AbbVie gains rights to FutureGen’s inflammatory bowel disease candidate in deal worth $1.7bn
The agreement gives AbbVie exclusive global rights to the TL1A-targeting monoclonal antibody
Read More
The agreement gives AbbVie exclusive global rights to the TL1A-targeting monoclonal antibody
Read MoreThe ability of oligonucleotides to modulate gene expression makes them an attractive modality for drugmakers
Read MoreThe agreement gives the company global rights to QRL-204 and other UNC13A-targeting compounds
Read MoreMerck will gain access to EyeBio’s Restoret to prevent and treat retinal vascular leakage-associated vision loss
Read MoreThe company will expand its immunology portfolio by gaining global rights to YJT’s NM26 in atopic dermatitis
Read MoreThe companies will focus on targets in oncology, neuroscience and inflammation
Read MoreThe deal aims to advance Merck’s viral vector manufacturing of cell and gene therapies
Read MoreThe company will gain access to HI-Bio’s lead asset for immune-mediated and rare diseases
Read MoreLilly will gain rights to develop Aktis’ lead programme targeting a tumour-associated antigen
Read MoreThe company expects to launch 20 new medicines by the end of the decade
Read MoreThe company will gain access to two treatments for atopic dermatitis
Read MoreLosmapimod is being investigated as a potential transformative therapy for the rare disease
Read MoreIntegrated Care Specialist - North & West Yorkshire
Territory Sales Manager - Yorkshire/North East
Territory Sales Manager - North London & East Anglia
Key Account Manager - Urology - East Anglia, Beds & Bucks
Territory Sales Manager - Ostomy Care - S Central/SW England